Novartis's EU Zykadia approval fills NSCLC treatment gap
This article was originally published in Scrip
Executive Summary
Novartis's lung cancer drug Zykadia (ceritinib) has been given the green light in Europe. The European Medicines Agency's scientific committee, the CHMP, granted a positive opinion in February this year for Zykadia, to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib (Pfizer's Xalkori). It is now the first specifically approved treatment option for this patient population.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.